Pacira BioSciences Inc(PCRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 72.51 | EPS (ttm) | 0.35 | Insider Own | 4.21% | Shs Outstand | 39.8M | Perf Week | -5.34% |
| Market Cap | 1.00B | Forward P/E | 7.32 | EPS next Y | 18.95% | Insider Trans | -2.79% | Shs Float | 38.2M | Perf Month | 3.2% |
| Enterprise Value | 1.16B | PEG | 0.37 | EPS next Q | 0.72 | Inst Own | 112.39% | Short Float | 19.11% | Perf Quarter | 7.43% |
| Income | 0.01B | P/S | 1.34 | EPS this Y | 9.04% | Inst Trans | 0.94% | Short Ratio | 12.92 | Perf Half Y | 10.21% |
| Sales | 0.75B | P/B | 1.49 | EPS next 5Y | 19.66% | ROA | 1.05% | Short Interest | 7.30M | Perf YTD | -2.78% |
| Book/sh | 16.87 | P/C | 4 | EPS past 3/5Y | -22.97% -45.77% | ROE | 2.05% | 52W High | -9.04% ($27.66) | Perf Year | -5.45% |
| Cash/sh | 6.3 | P/FCF | 5.59 | Sales past 3/5Y | 2.89% 11.07% | ROIC | 1.36% | 52W Low | 33.83% ($18.80) | Perf 3Y | -25.45% |
| Dividend Est. | - | EV/EBITDA | 10.32 | EPS Y/Y TTM | 112.73% | Gross Margin | 71.53% | Volatility(W/M) | 2.33% 2.83% | Perf 5Y | -54.58% |
| Dividend TTM | - | EV/Sales | 1.56 | Sales Y/Y TTM | 5.71% | Oper. Margin | 3.7% | ATR (14) | 0.76 | Perf 10Y | -35.37% |
| Dividend Ex-Date | - | Quick Ratio | 3.94 | EPS Q/Q | 208.35% | Profit Margin | 1.96% | RSI (14) | 46.86 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | 6.24% | SMA20 | 0.05% ($25.15) | Beta | 0.25 | Target Price | $29.75 |
| Payout | - | Debt/Eq | 0.61 | Earnings | 2026/8/4 | SMA50 | -1.14% ($25.45) | Rel Volume | 1.26 | Prev Close | $25.88 |
| Employees | 829 | LT Debt/Eq | 0.6 | EPS/Sales Surpr. | 12.95% 0.7% | SMA200 | 5.48% ($23.85) | Avg Volume(3M) | 0.56M | Price | $25.16 |
| IPO | 2011/2/3 | Option/Short | Yes/Yes | Trades | 7296 | Volume | 711,376 | Change | -2.78% |
Company
PCRX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 Pacira BioSciences (PCRX) is a US specialty pharmaceutical company focused on non-opioid pain management. Its flagship product is EXPAREL, a post-surgical pain relief injection, and the company also operates ZILRETTA, a treatment for knee osteoarthritis, and the iovera system, a cryoanalgesia (cold-based nerve-blocking) device, giving it a product lineup that targets the full range of neuropathic pain pathways.
Over the past 1 year, roughly in the middle
9% below its 1-year high.
PCRX makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +9.0% this year.
Tap to view numbers
The stock looks undervalued
Trading at 72.5 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -25.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 112.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XPH 0.02%
PILL 0.01%
RNIN 0.01%
SIXS 0.01%
ACVT 0.01%It ranks #4 in the industry
Based on market cap of $1B.
PCRX $1B PER 72.5
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is PCRX?
PCRX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PCRX?
The market cap of PCRX is approximately $1.0B, ranking 2,651 within its sector.
What is the P/E ratio of PCRX?
PCRX has a P/E ratio of approximately 72.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PCRX?
PCRX has recorded a 52-week high of $27.66 and a low of $18.80.
